Kari Kivistö

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Procedures

Concepts & Ideas

Chemicals & Drugs

Physiology

Drug Interactions

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Mörike K; Kivistö K T; Schaeffeler E; Jägle C; Igel S; Drescher S; Fux R; Marx C; Hofmann U; Engel C; Wagner F; Delabar U; Meisner C; Bail D; Böhm J O; Gleiter C H; Ziemer G; Rein J G; Hellberg K D; Eichelbaum M; Schwab M
Propafenone for the prevention of atrial tachyarrhythmias after cardiac surgery: a randomized, double-blind placebo-controlled trial.
Kivistö Kari T; Niemi Mikko
Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.
Niemi Mikko; Arnold Katja A; Backman Janne T; Pasanen Marja K; Gödtel-Armbrust Ute; Wojnowski Leszek; Zanger Ulrich M; Neuvonen Pertti J; Eichelbaum Michel; Kivistö Kari T; Lang Thomas
Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Kari Kivistö (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2008: Mörike K; Kivistö K T; Schaeffeler E; Jägle C; Igel S; Drescher S; Fux R; Marx C; Hofmann U; Engel C; Wagner F; Delabar U; Meisner C; Bail D; Böhm J O; Gleiter C H; Ziemer G; Rein J G; Hellberg K D; Eichelbaum M; Schwab M
Propafenone for the prevention of atrial tachyarrhythmias after cardiac surgery: a randomized, double-blind placebo-controlled trial.
Clinical pharmacology and therapeutics 2008;84(1):104-10.
2007: Kivistö Kari T; Niemi Mikko
Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.
Pharmaceutical research 2007;24(2):239-47.
2006: Niemi Mikko; Arnold Katja A; Backman Janne T; Pasanen Marja K; Gödtel-Armbrust Ute; Wojnowski Leszek; Zanger Ulrich M; Neuvonen Pertti J; Eichelbaum Michel; Kivistö Kari T; Lang Thomas
Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.
Pharmacogenetics and genomics 2006;16(11):801-8.
2006: Niemi Mikko; Kivistö Kari T; Diczfalusy Ulf; Bodin Karl; Bertilsson Leif; Fromm Martin F; Eichelbaum Michel
Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin.
Pharmacogenetics and genomics 2006;16(8):565-8.
2006: Busse Dagmar; Templin Silke; Mikus Gerd; Schwab Matthias; Hofmann Ute; Eichelbaum Michel; Kivistö Kari T
Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study.
European journal of clinical pharmacology 2006;62(8):613-9.
2006: Hedman Mia; Antikainen Marjatta; Holmberg Christer; Neuvonen Mikko; Eichelbaum Michel; Kivistö Kari T; Neuvonen Pertti J; Niemi Mikko
Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes.
British journal of clinical pharmacology 2006;61(6):706-15.
2006: Igel Michael; Arnold Katja A; Niemi Mikko; Hofmann Ute; Schwab Matthias; Lütjohann Dieter; von Bergmann Klaus; Eichelbaum Michel; Kivistö Kari T
Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin.
Clinical pharmacology and therapeutics 2006;79(5):419-26.
2006: Kivistö Kari T
Comments on "Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: Application of in vitro and ex situ systems".
The Journal of pharmacology and experimental therapeutics 2006;316(3):1386; author reply 1387.
2006: Soininen Kari; Niemi Mikko; Kilkki Esa; Strandberg Timo; Kivistö Kari T
Muscle symptoms associated with statins: a series of twenty patients.
Basic & clinical pharmacology & toxicology 2006;98(1):51-4.
2005: Kivistö Kari T; Grisk Olaf; Hofmann Ute; Meissner Konrad; Möritz Klaus-Uwe; Ritter Christoph; Arnold Katja A; Lutjöohann Dieter; von Bergmann Klaus; Klöting Ingrid; Eichelbaum Michel; Kroemer Heyo K
Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(11):1593-6.
2005: Fux Richard; Mörike Klaus; Pröhmer Anne M T; Delabar Ursula; Schwab Matthias; Schaeffeler Elke; Lorenz Gernot; Gleiter Christoph H; Eichelbaum Michel; Kivistö Kari T
Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
Clinical pharmacology and therapeutics 2005;78(4):378-87.
2005: Niemi Mikko; Backman Janne T; Kajosaari Lauri I; Leathart Julian B; Neuvonen Mikko; Daly Ann K; Eichelbaum Michel; Kivistö Kari T; Neuvonen Pertti J
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
Clinical pharmacology and therapeutics 2005;77(6):468-78.
2005: Niemi Mikko; Neuvonen Pertti J; Hofmann Ute; Backman Janne T; Schwab Matthias; Lütjohann Dieter; von Bergmann Klaus; Eichelbaum Michel; Kivistö Kari T
Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17.
Pharmacogenetics and genomics 2005;15(5):303-9.
2005: Niemi Mikko; Kivistö Kari T; Hofmann Ute; Schwab Matthias; Eichelbaum Michel; Fromm Martin F
Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1).
British journal of clinical pharmacology 2005;59(5):602-4.
2005: Kahri Juhani; Valkonen Miia; Bäcklund Tom; Vuoristo Matti; Kivistö Kari T
Rhabdomyolysis in a patient receiving atorvastatin and fluconazole.
European journal of clinical pharmacology 2005;60(12):905-7.
2005: Kivistö Kari T; Niemi Mikko; Schaeffeler Elke; Pitkälä Kaisu; Tilvis Reijo; Fromm Martin F; Schwab Matthias; Lang Florian; Eichelbaum Michel; Strandberg Timo
CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study.
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 2005;5(3):191-5.
2004: Kivistö Kari T; Niemi Mikko; Fromm Martin F
Functional interaction of intestinal CYP3A4 and P-glycoprotein.
Fundamental & clinical pharmacology 2004;18(6):621-6.
2004: Kivistö Kari T; Zukunft Jörg; Hofmann Ute; Niemi Mikko; Rekersbrink Sabine; Schneider Swetlana; Luippold Gerd; Schwab Matthias; Eichelbaum Michel; Fromm Martin F
Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.
Naunyn-Schmiedeberg's archives of pharmacology 2004;370(2):124-30.
2004: Kivistö Kari T; Niemi Mikko; Schaeffeler Elke; Pitkälä Kaisu; Tilvis Reijo; Fromm Martin F; Schwab Matthias; Eichelbaum Michel; Strandberg Timo
Lipid-lowering response to statins is affected by CYP3A5 polymorphism.
Pharmacogenetics 2004;14(8):523-5.
2004: Niemi Mikko; Schaeffeler Elke; Lang Thomas; Fromm Martin F; Neuvonen Mikko; Kyrklund Carl; Backman Janne T; Kerb Reinhold; Schwab Matthias; Neuvonen Pertti J; Eichelbaum Michel; Kivistö Kari T
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).
Pharmacogenetics 2004;14(7):429-40.
2004: von Richter Oliver; Burk Oliver; Fromm Martin F; Thon Klaus P; Eichelbaum Michel; Kivistö Kari T
Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens.
Clinical pharmacology and therapeutics 2004;75(3):172-83.
2003: Läpple Florian; von Richter Oliver; Fromm Martin F; Richter Tanja; Thon Klaus P; Wisser Hermann; Griese Ernst-Ulrich; Eichelbaum Michel; Kivistö Kari T
Differential expression and function of CYP2C isoforms in human intestine and liver.
Pharmacogenetics 2003;13(9):565-75.
2003: Niemi Mikko; Backman Janne T; Fromm Martin F; Neuvonen Pertti J; Kivistö Kari T
Pharmacokinetic interactions with rifampicin : clinical relevance.
Clinical pharmacokinetics 2003;42(9):819-50.
2002: Geisel Jürgen; Kivistö Kari T; Griese Ernst-Ulrich; Eichelbaum Michel
The efficacy of simvastatin is not influenced by CYP2D6 polymorphism.
Clinical pharmacology and therapeutics 2002;72(5):595-6.
2002: Raaska Kari; Niemi Mikko; Neuvonen Mikko; Neuvonen Pertti J; Kivistö Kari T
Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.
Clinical pharmacology and therapeutics 2002;72(4):362-9.
2002: Niemi Mikko; Cascorbi Ingolf; Timm Ramona; Kroemer Heyo K; Neuvonen Pertti J; Kivistö Kari T
Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
Clinical pharmacology and therapeutics 2002;72(3):326-32.
2001: Wen X; Wang J S; Kivistö K T; Neuvonen P J; Backman J T
In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
British journal of clinical pharmacology 2001;52(5):547-53.
2001: Niemi M; Neuvonen P J; Kivistö K T
Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride.
Clinical pharmacology and therapeutics 2001;70(5):439-45.
2001: Wen X; Wang J S; Backman J T; Kivistö K T; Neuvonen P J
Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(11):1359-61.
2001: Villikka K; Varis T; Backman J T; Neuvonen P J; Kivistö K T
Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo.
European journal of clinical pharmacology 2001;57(6-7):457-60.
2001: Lapatto-Reiniluoto O; Kivistö K T; Neuvonen P J
Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs.
Clinical pharmacology and therapeutics 2001;70(3):255-60.
2001: Niemi M; Neuvonen P J; Kivistö K T
The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide.
Clinical pharmacology and therapeutics 2001;70(1):58-65.
2001: Niemi M; Backman J T; Neuvonen M; Neuvonen P J; Kivistö K T
Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide.
Clinical pharmacology and therapeutics 2001;69(6):400-6.
2001: Kyrklund C; Backman J T; Kivistö K T; Neuvonen M; Laitila J; Neuvonen P J
Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate.
Clinical pharmacology and therapeutics 2001;69(5):340-5.
2001: Kivistö K T; Wang J S; Backman J T; Nyman L; Taavitsainen P; Anttila M; Neuvonen P J
Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.
European journal of clinical pharmacology 2001;57(1):37-42.
2001: Niemi M; Backman J T; Neuvonen M; Laitila J; Neuvonen P J; Kivistö K T
Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.
Clinical pharmacology and therapeutics 2001;69(4):194-200.
2000: Kyrklund C; Backman J T; Kivistö K T; Neuvonen M; Laitila J; Neuvonen P J
Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations.
Clinical pharmacology and therapeutics 2000;68(6):592-7.
2000: Niemi M; Kivistö K T; Backman J T; Neuvonen P J
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride.
British journal of clinical pharmacology 2000;50(6):591-5.
2000: Pohjola-Sintonen S; Kivistö K T; Vuori E; Lapatto-Reiniluoto O; Tiula E; Neuvonen P J
Identification of drugs ingested in acute poisoning: correlation of patient history with drug analyses.
Therapeutic drug monitoring 2000;22(6):749-52.
2000: Wang J S; Backman J T; Kivistö K T; Neuvonen P J
Effects of metronidazole on midazolam metabolism in vitro and in vivo.
European journal of clinical pharmacology 2000;56(8):555-9.
2000: Niemi M; Backman J T; Neuvonen M; Neuvonen P J; Kivistö K T
Rifampin decreases the plasma concentrations and effects of repaglinide.
Clinical pharmacology and therapeutics 2000;68(5):495-500.
2000: Varis T; Kivistö K T; Backman J T; Neuvonen P J
The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect.
Clinical pharmacology and therapeutics 2000;68(5):487-94.
2000: Lilja J J; Kivistö K T; Neuvonen P J
Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin.
Clinical pharmacology and therapeutics 2000;68(4):384-90.
2000: Varis T; Kivistö K T; Neuvonen P J
Grapefruit juice can increase the plasma concentrations of oral methylprednisolone.
European journal of clinical pharmacology 2000;56(6-7):489-93.
2000: Lilja J J; Kivistö K T; Backman J T; Neuvonen P J
Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life.
European journal of clinical pharmacology 2000;56(5):411-5.
2000: Backman J T; Kyrklund C; Kivistö K T; Wang J S; Neuvonen P J
Plasma concentrations of active simvastatin acid are increased by gemfibrozil.
Clinical pharmacology and therapeutics 2000;68(2):122-9.
2000: Wang J S; Backman J T; Taavitsainen P; Neuvonen P J; Kivistö K T
Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(8):959-65.
2000: Lapatto-Reiniluoto O; Kivistö K T; Neuvonen P J
Efficacy of activated charcoal versus gastric lavage half an hour after ingestion of moclobemide, temazepam, and verapamil.
European journal of clinical pharmacology 2000;56(4):285-8.
2000: Kantola T; Backman J T; Niemi M; Kivistö K T; Neuvonen P J
Effect of fluconazole on plasma fluvastatin and pravastatin concentrations.
European journal of clinical pharmacology 2000;56(3):225-9.
2000: Varis T; Kivistö K T; Neuvonen P J
The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone.
European journal of clinical pharmacology 2000;56(1):57-60.
2000: Backman J T; Mäenpää J; Belle D J; Wrighton S A; Kivistö K T; Neuvonen P J
Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation.
Clinical pharmacology and therapeutics 2000;67(4):382-90.
2000: Varis T; Backman J T; Kivistö K T; Neuvonen P J
Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.
Clinical pharmacology and therapeutics 2000;67(3):215-21.
2000: Lapatto-Reiniluoto O; Kivistö K T; Neuvonen P J
Gastric decontamination performed 5 min after the ingestion of temazepam, verapamil and moclobemide: charcoal is superior to lavage.
British journal of clinical pharmacology 2000;49(3):274-8.
1999: Villikka K; Kivistö K T; Mäenpää H; Joensuu H; Neuvonen P J
Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors.
Clinical pharmacology and therapeutics 1999;66(6):589-93.
1999: Wang J S; Backman J T; Wen X; Taavitsainen P; Neuvonen P J; Kivistö K T
Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro.
Pharmacology & toxicology 1999;85(5):201-5.
1999: Kivistö K T; Lilja J J; Backman J T; Neuvonen P J
Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride.
Clinical pharmacology and therapeutics 1999;66(5):448-53.
1999: Wang J S; Wen X; Backman J T; Taavitsainen P; Neuvonen P J; Kivistö K T
Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole.
Pharmacology & toxicology 1999;85(4):157-61.
1999: Backman J T; Wang J S; Wen X; Kivistö K T; Neuvonen P J
Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam.
Clinical pharmacology and therapeutics 1999;66(4):401-7.
1999: Lilja J J; Kivistö K T; Neuvonen P J
Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.
Clinical pharmacology and therapeutics 1999;66(2):118-27.
1999: Lapatto-Reiniluoto O; Kivistö K T; Neuvonen P J
Effect of activated charcoal alone or given after gastric lavage in reducing the absorption of diazepam, ibuprofen and citalopram.
British journal of clinical pharmacology 1999;48(2):148-53.
1999: Varis T; Kivistö K T; Backman J T; Neuvonen P J
Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers.
Pharmacology & toxicology 1999;85(1):29-32.
1999: Kivistö K T; Laitila J; Mårtensson K; Neuvonen P J
Determination of buspirone and 1-(2-pyrimidinyl)-piperazine (1-PP) in human plasma by capillary gas chromatography.
Therapeutic drug monitoring 1999;21(3):317-21.
1999: Lamberg T S; Kivistö K T; Neuvonen P J
Lack of effect of terfenadine on the pharmacokinetics of the CYP3A4 substrate buspirone.
Pharmacology & toxicology 1999;84(4):165-9.
1999: Villikka K; Kivistö K T; Neuvonen P J
The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron.
Clinical pharmacology and therapeutics 1999;65(4):377-81.
1999: Kivistö K T; Lamberg T S; Neuvonen P J
Interactions of buspirone with itraconazole and rifampicin: effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone.
Pharmacology & toxicology 1999;84(2):94-7.
1999: Kantola T; Kivistö K T; Neuvonen P J
Effect of itraconazole on cerivastatin pharmacokinetics.
European journal of clinical pharmacology 1999;54(11):851-5.
1998: Lilja J J; Kivistö K T; Backman J T; Lamberg T S; Neuvonen P J
Grapefruit juice substantially increases plasma concentrations of buspirone.
Clinical pharmacology and therapeutics 1998;64(6):655-60.
1998: Kivistö K T; Villikka K; Nyman L; Anttila M; Neuvonen P J
Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin.
Clinical pharmacology and therapeutics 1998;64(6):648-54.
1998: Lamberg T S; Kivistö K T; Laitila J; Mårtensson K; Neuvonen P J
The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone.
European journal of clinical pharmacology 1998;54(9-10):761-6.
1998: Lilja J J; Kivistö K T; Neuvonen P J
Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.
Clinical pharmacology and therapeutics 1998;64(5):477-83.
1998: Varis T; Kaukonen K M; Kivistö K T; Neuvonen P J
Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.
Clinical pharmacology and therapeutics 1998;64(4):363-8.
1998: Villikka K; Kivistö K T; Neuvonen P J
The effect of dexamethasone on the pharmacokinetics of triazolam.
Pharmacology & toxicology 1998;83(3):135-8.
1998: Kantola T; Kivistö K T; Neuvonen P J
Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations.
Clinical pharmacology and therapeutics 1998;64(2):177-82.
1998: Kantola T; Kivistö K T; Neuvonen P J
Effect of itraconazole on the pharmacokinetics of atorvastatin.
Clinical pharmacology and therapeutics 1998;64(1):58-65.
1998: Kivistö K T; Kantola T; Neuvonen P J
Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin.
British journal of clinical pharmacology 1998;46(1):49-53.
1998: Lapatto-Reiniluoto O; Kivistö K T; Pohjola-Sintonen S; Luomanmäki K; Neuvonen P J
A prospective study of acute poisonings in Finnish hospital patients.
Human & experimental toxicology 1998;17(6):307-11.
1998: Lamberg T S; Kivistö K T; Neuvonen P J
Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone.
Clinical pharmacology and therapeutics 1998;63(6):640-5.
1998: Luurila H; Kivistö K T; Neuvonen P J
Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem.
European journal of clinical pharmacology 1998;54(2):163-6.
1998: Kantola T; Kivistö K T; Neuvonen P J
Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.
Clinical pharmacology and therapeutics 1998;63(4):397-402.
1998: Lamberg T S; Kivistö K T; Neuvonen P J
Concentrations and effects of buspirone are considerably reduced by rifampicin.
British journal of clinical pharmacology 1998;45(4):381-5.
1998: Backman J T; Kivistö K T; Olkkola K T; Neuvonen P J
The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.
European journal of clinical pharmacology 1998;54(1):53-8.
1998: Neuvonen P J; Kantola T; Kivistö K T
Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.
Clinical pharmacology and therapeutics 1998;63(3):332-41.
1997: Villikka K; Kivistö K T; Luurila H; Neuvonen P J
Rifampin reduces plasma concentrations and effects of zolpidem.
Clinical pharmacology and therapeutics 1997;62(6):629-34.
1997: Lapatto O; Kivistö K T; Salorinne Y
The effects of glyceryl trinitrate and nicotinic acid ointments during cold exposure.
Pharmacology & toxicology 1997;81(5):238-41.
1997: Kivistö K T; Lamberg T S; Kantola T; Neuvonen P J
Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole.
Clinical pharmacology and therapeutics 1997;62(3):348-54.
1997: Kivistö K T; Griese E U; Stüven T; Fritz P; Friedel G; Kroemer H K; Zanger U M
Analysis of CYP2D6 expression in human lung: implications for the association between CYP2D6 activity and susceptibility to lung cancer.
Pharmacogenetics 1997;7(4):295-302.
1997: Villikka K; Kivistö K T; Lamberg T S; Kantola T; Neuvonen P J
Concentrations and effects of zopiclone are greatly reduced by rifampicin.
British journal of clinical pharmacology 1997;43(5):471-4.
1997: Luomanmäki K; Tiula E; Kivistö K T; Neuvonen P J
Pharmacokinetics of diltiazem in massive overdose.
Therapeutic drug monitoring 1997;19(2):240-2.
1997: Kivistö K T; Kroemer H K
Use of probe drugs as predictors of drug metabolism in humans.
Journal of clinical pharmacology 1997;37(1 Suppl):40S-48S.
1997: Villikka K; Kivistö K T; Backman J T; Olkkola K T; Neuvonen P J
Triazolam is ineffective in patients taking rifampin.
Clinical pharmacology and therapeutics 1997;61(1):8-14.
1997: Kivistö K T; Neuvonen P J; Tarssanen L
Pharmacokinetics of verapamil in overdose.
Human & experimental toxicology 1997;16(1):35-7.
1994: Neuvonen P J; Kivistö K T
Enhancement of drug absorption by antacids. An unrecognised drug interaction.
Clinical pharmacokinetics 1994;27(2):120-8.
1990: Hirvisalo E L; Kivistö K T; Neuvonen P J
Therapeutic cyclosporine monitoring: comparison of radioimmunoassay and high-performance liquid chromatography methods in organ transplant recipients.
Therapeutic drug monitoring 1990;12(4):353-8.
1989: Neuvonen P J; Kivistö K T
The clinical significance of food-drug interactions: a review.
The Medical journal of Australia 1989;150(1):36-40.
1988: Neuvonen P J; Kivistö K; Hirvisalo E L
Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide.
British journal of clinical pharmacology 1988;25(2):229-33.
1988: Neuvonen P J; Kivistö K T
Effect of magnesium hydroxide on the absorption of tolfenamic and mefenamic acids.
European journal of clinical pharmacology 1988;35(5):495-501.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Kari Kivistö

Research Profile (preview)

Procedures

Concepts & Ideas

Chemicals & Drugs

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Kari Kivistö (preview)

All Publications